Compare Vanguard Short Term Corporate Bond ETF (VCSH) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Short Term Corporate Bond ETF vs Zoetis Inc — how do they compare? Vanguard Short Term Corporate Bond ETF trades at $77.3 (market cap $51.90B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Vanguard Short Term Corporate Bond ETF is the larger of the two by market cap, and Zoetis Inc pays a 2.9% dividend while Vanguard Short Term Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Short Term Corporate Bond ETF for 52 Days and Zoetis Inc for 70 Days on average.
| VCSH | ZTS | |
|---|---|---|
Market Cap | $51.90B | $30.20B |
Volume | 2,892,221 | 6,175,327 |
Sector | Fixed Income | Health |
52-Week High | $80.20 | $147.53 |
52-Week Low | $77.03 | $69.09 |
Typical Hold Time | 52 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VCSH, the Vanguard Short-Term Corporate Bond ETF, trades at $77.34 with a slight 0.09% daily gain. The technical outlook is bearish based on moving averages, while oscillators are neutral. Recent news highlights its competitive 4.5% dividend yield and low 0.03% expense ratio, though some analysts note tight credit spreads and downgrade it to 'Hold'. The fund's short 2.7-year duration minimizes interest rate risk but carries corporate credit exposure.
The ETF offers a higher yield than treasury alternatives but faces headwinds from limited price appreciation potential amid rising rates and compressed spreads. Key risks include credit deterioration and institutional selling. Analyst sentiment is mixed, balancing yield appeal against near-term unattractive entry points.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
